BRUKER (BRKR) Company Report

Bruker reported Q4 2025 revenues of $977.2 million, which were approximately flat year-over-year with a 5.1% organic decline, and non-GAAP diluted EPS of $0.59. The company generated $207.3 million in free cash flow during the quarter.
For the full fiscal year 2025, reported revenues increased by 2.1% to $3.44 billion, with an organic decline of 3.7%, and the non-GAAP operating margin was 12.6%.
For fiscal year 2026, Bruker is guiding for reported revenue of $3.57 billion-$3.60 billion (representing 4%-5% growth), 1%-2% organic revenue growth, 250-300 basis points of non-GAAP operating margin expansion, and non-GAAP EPS of $2.10-$2.15 (15%-17% growth).
The company anticipates a mid-single-digit organic revenue decline in Q1 2026, with organic revenue growth expected to resume in Q2 2026 and for the remainder of the year.
Cost-saving initiatives are now expected to exceed $120 million, contributing to the projected margin improvement.

Feb 12, 2026, 1:30 PM

Transcript

Bruker Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker reported Q4 2025 revenues of $977.2 million, approximately flat year-over-year, with an organic decline of 5.1%, and non-GAAP diluted EPS of $0.59. Full year 2025 revenues increased 2.1% to $3.44 billion, with an organic decline of 3.7%.
For fiscal year 2026, the company expects reported revenue of $3.57 billion-$3.60 billion (4%-5% growth) and 1%-2% organic revenue growth.
Management projects a mid-single-digit organic revenue decline in Q1 2026, followed by a return to organic revenue growth in the second quarter and for the remainder of the year.
Bruker aims for 250 basis points-300 basis points non-GAAP operating profit margin improvement and 15%-17% non-GAAP EPS growth in fiscal year 2026.

Feb 12, 2026, 1:30 PM

Transcript

Bruker Corporation Reports Q4 and Full-Year 2025 Results and Provides 2026 Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker Corporation (BRKR) reported Q4 2025 revenue of $977.2 million, a 0.2% decrease year-over-year, with non-GAAP EPS declining 22.4% to $0.59.
For full-year 2025, revenue grew 2.1% to $3,436.5 million, but non-GAAP EPS decreased 24.1% to $1.83, primarily impacted by demand, tariff, and FX headwinds.
The company provided FY 2026 guidance, forecasting revenue between $3.57 billion and $3.60 billion (a 4% to 5% reported increase) and non-GAAP EPS of $2.10 to $2.15 (a 15% to 17% reported increase).
FY 2026 organic revenue growth is projected at 1% to 2%, with an anticipated operating margin increase of 250-300 bps, though an FX headwind of approximately $0.15 to EPS is expected.

Feb 12, 2026, 1:30 PM

Presentation

Bruker Reports Q4 and Full Year 2025 Results, Issues 2026 Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker reported Q4 2025 revenues of $977.2 million, which were approximately flat year-over-year, reflecting a 5.1% organic decline, and non-GAAP diluted EPS of $0.59. The company generated $207.3 million in free cash flow during the quarter.
For the full fiscal year 2025, reported revenues increased 2.1% to $3.44 billion, while organic revenues declined 3.7%. The non-GAAP operating margin for FY 2025 was 12.6%, down 280 basis points year-over-year.
For fiscal year 2026, Bruker is guiding for reported revenue growth of 4%-5%, reaching $3.57 billion-$3.60 billion, with 1%-2% organic revenue growth. The company also expects non-GAAP operating margin expansion of 250-300 basis points and non-GAAP EPS growth of 15%-17%.
Bruker anticipates a mid-single-digit organic revenue decline in Q1 2026 due to strong prior-year comparisons, with organic revenue growth expected to resume in Q2 2026. Cost-saving initiatives are now projected to exceed $140 million on an annualized basis.

Feb 12, 2026, 1:30 PM

Transcript

Bruker Reports Q4 and Full Year 2025 Financial Results, Initiates FY26 Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker reported Q4 2025 revenues of $977.2 million, which were flat year-over-year, and non-GAAP diluted EPS of $0.59.
For the full year 2025, revenues reached $3.44 billion, an increase of 2.1% year-over-year, with non-GAAP diluted EPS of $1.83.
The company initiated its FY 2026 guidance, projecting revenues between $3.57 and $3.60 billion (up 4% to 5% year-over-year) and non-GAAP EPS of $2.10 to $2.15 (up 15% to 17% year-over-year).
CEO Frank H. Laukien noted a "difficult year 2025" but expressed optimism for "very significant operating margin expansion and double-digit EPS growth in 2026" driven by market recovery.

Feb 12, 2026, 12:00 PM

8-K

Bruker Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates 2026 Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

**Bruker reported Q4 2025 revenues of $977.2 million, which were flat year-over-year, with an organic decrease of approximately 5%. For the full year 2025, revenues were $3.44 billion, an increase of approximately 2% year-over-year, but decreased approximately 4% organically. **
**Q4 2025 GAAP diluted EPS was $0.10, while non-GAAP diluted EPS was $0.59. For the full year 2025, the company reported a GAAP diluted loss per share of $(0.15) and non-GAAP diluted EPS of $1.83. **
**Bruker initiated its FY 2026 guidance, expecting revenues of $3.57 billion to $3.60 billion, representing 4% to 5% year-over-year growth, with organic growth projected at 1% to 2%. **
**The company also provided FY 2026 non-GAAP EPS guidance of $2.10 to $2.15, indicating a 15% to 17% increase year-over-year. **

Feb 12, 2026, 12:00 PM

Press Release

Bruker Corporation Provides Preliminary Q4 2025 Revenue and FY 2026 Outlook

BRKR

Earnings

Guidance Update

Bruker Corporation announced on January 12, 2026, its preliminary expectation for revenue for the fourth quarter ended December 31, 2025, to be between $965 million and $970 million.
The Bruker Scientific Instruments segments book-to-bill ratio for Q4 2025 was above 1.0.
For the full year ending December 31, 2026, the company provided a preliminary outlook for organic revenue growth of flat to up low-single digits, non-GAAP organic operating margins to expand 250 to 300 basis points, and non-GAAP earnings per share to grow in the double-digits, all compared to full year 2025.

Jan 12, 2026, 5:00 PM

8-K

Bruker Corporation Provides 2026 Outlook and Strategic Focus at J.P. Morgan Conference

BRKR

Guidance Update

New Projects/Investments

Demand Weakening

Bruker Corporation reported preliminary Q4 2025 revenue between $965 million and $970 million and full-year 2025 reported revenue of approximately $3.43 billion, representing about 2% growth.
Following a "rough year" in 2025, Bruker's focus for 2026 and the next three to five years is on profitability, aiming for a transformative margin and EPS jump from mid-teens to low to mid-20s margins and double-digit EPS growth.
The company anticipates $120 million in anticipated cost savings in 2026, contributing to a preliminary 2026 outlook of flat to low single-digit organic revenue growth (constant exchange rate), 250-300 basis points organic operating profit margin expansion, and double-digit non-GAAP EPS growth.
Bruker is evolving "Project Accelerate" into "Project Accelerate 3.0," emphasizing aftermarket and sticky revenues and expanding into new opportunities in clinical microbiology, molecular diagnostics (a $500 million business), and automated AI lab tools (a $100 million business).
Recent product launches, including the TIMS Omni and TIMS Metabo mass spectrometers and the CosMx Whole Transcriptome Panel, are showing good traction, with the Wave Rapid AST platform anticipated for a U.S. launch in 2026 pending FDA clearance.

Jan 12, 2026, 5:00 PM

Transcript

Bruker Discusses 2025 Performance and 2026 Strategic Focus

BRKR

Guidance Update

Product Launch

New Projects/Investments

Bruker reported preliminary Q4 2025 revenue between $965 million and $970 million, contributing to a full-year 2025 preliminary revenue of approximately $3.43 billion, up about 2%. The company noted 2025 was a "rough year" with organic revenue down, but constant exchange rate revenue was flat.
For 2026, Bruker's strategic focus is on profitability, aiming for a transformative margin and EPS jump, with a goal to increase margins from the mid-teens to the low to mid-20s and deliver double-digit EPS growth over the next three to five years.
The company is targeting $120 million in cost savings for 2026, encompassing both COGS and OPEX, to drive significant margin improvement and double-digit EPS growth.
The preliminary outlook for 2026 includes flat to low single-digit organic revenue growth (non-GAAP constant exchange rate), 250-300 basis points of organic operating profit margin expansion, and double-digit non-GAAP EPS growth.
Bruker highlighted new product launches, such as the TIMS Omni and CosMx Whole Transcriptome Panel, and strategic opportunities in clinical microbiology, molecular diagnostics for infectious diseases, and automated AI lab tools as key growth drivers.

Jan 12, 2026, 5:00 PM

Transcript

Bruker Provides 2026 Outlook and Strategic Update at J.P. Morgan Conference

BRKR

Guidance Update

New Projects/Investments

Product Launch

Bruker reported preliminary Q4 2025 revenue between $965 million and $970 million, approximately $10 million above consensus, with full-year 2025 reported revenue reaching about $3.43 billion, an increase of 2%. The book-to-bill ratio for its BSI segment was just above 1.0 in Q4 2025.
For 2026, the company anticipates flat to low single-digit organic revenue growth at constant exchange rates, while aiming for 250-300 basis points of organic operating profit margin expansion and double-digit non-GAAP EPS growth. These improvements are expected to be driven by $120 million in cost reductions across COGS and OPEX.
Bruker is evolving Project Accelerate into Project Accelerate 3.0, with a focus on profitability, transformative margin, and sticky aftermarket revenues. Key growth areas include clinical microbiology and molecular diagnostics (an approximately $500 million business with 65-75% aftermarket revenue and above-average margins), automated AI lab tools (currently generating about $100 million in revenue), and defense detection.
The company's spatial biology business grew in low double digits in 2025, and it launched new multi-omics mass spectrometers, including the TIMS Omni, a $1.5 million instrument that has already received orders from biopharma. Bruker also plans to launch the Wave Rapid AST platform in the U.S. market in 2026, pending FDA clearance.

Jan 12, 2026, 5:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for BRUKER.

Q4 2025

Feb 12, 2026

→

Q3 2025

Nov 3, 2025

→

Q2 2025

Aug 4, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Frank H. Laukien say about margins?What are BRUKER's strategic priorities?How is BRUKER positioned vs competitors?How did BRUKER do last quarter?

BRUKER (BRKR)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Frank H. Laukien

Burkhard A. Prause

Falko Busse

Gerald N. Herman

Juergen W. Srega

Mark R. Munch

Board Members

Adelene Q. Perkins

Bonnie H. Anderson

Cynthia M. Friend

Hermann F. Requardt

John A. Ornell

Laura A. Francis

Richard A. Packer

Robert J. Rosenthal

William A. Linton

Analyst Coverage

Luke Sergott

Puneet Souda

Tycho Peterson

Michael Ryskin

Patrick Donnelly

Doug Schenkel

Rachel Vatnsdal Olson

Brandon Couillard

Dan Brennan

Daniel Brennan

Joshua Waldman

S. Brandon Couillard

Subbu Nambi

Subhalaxmi Nambi

Brandon Couillard

Douglas Schenkel

Marta Nazarovets Zaremba

Subbu Nambiar

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent